[go: up one dir, main page]

AR034037A1 - Inhibidor de aromatasa en dosis multiples para tratar la infertilidad - Google Patents

Inhibidor de aromatasa en dosis multiples para tratar la infertilidad

Info

Publication number
AR034037A1
AR034037A1 ARP020101400A ARP020101400A AR034037A1 AR 034037 A1 AR034037 A1 AR 034037A1 AR P020101400 A ARP020101400 A AR P020101400A AR P020101400 A ARP020101400 A AR P020101400A AR 034037 A1 AR034037 A1 AR 034037A1
Authority
AR
Argentina
Prior art keywords
daily doses
aromatase inhibitor
hormone
administering
folliculostimulant
Prior art date
Application number
ARP020101400A
Other languages
English (en)
Inventor
Robert Casper
Mohamed F M Mitwally
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of AR034037A1 publication Critical patent/AR034037A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para inducir la ovulación de un sujeto de sexo femenino que sufre de infertilidad anovulatoria que comprende administrar a dicho sujeto dos o más dosis diarias de al menos un inhibidor de aromatasa. Un método para aumentar la ovulación en un sujeto de sexo femenino que sufre de infertilidad sin causa aparente u otro tipo de infertilidad anovulatoria que comprende administrar a dicho sujeto de sexo femenino una combinación de dos o más dosis diarias de al menos un inhibidor de aromatasa en uno o más ciclos menstruales. Un método para reducir sustancialmente los niveles de dosificación de hormona folículostimulante (FSH) para administrar a una mujer que comprende administrar una combinación de dos o más dosis diarias de por lo menos un inhibidor de aromatasa (AI) con varias dosis diarias de hormona foliculostimulante (FSH). Un método para aumentar la respuesta a la hormona foliculostimulante de una mujer que tiene un bajo nivel de respuesta a la estimulación del folículo, que comprende administrar una combinación de dos o más dosis diarias de por lo menos un inhibidor de aromatasa (AI) con varias dosis diarias de hormona foliculostimulante (FSH). También se incluyen preparaciones farmacéuticas y usos.
ARP020101400A 2001-04-17 2002-04-17 Inhibidor de aromatasa en dosis multiples para tratar la infertilidad AR034037A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2001/000517 WO2002083146A1 (en) 2001-04-17 2001-04-17 Multiple dose aromatase inhibitor for treating infertility

Publications (1)

Publication Number Publication Date
AR034037A1 true AR034037A1 (es) 2004-01-21

Family

ID=4143137

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101400A AR034037A1 (es) 2001-04-17 2002-04-17 Inhibidor de aromatasa en dosis multiples para tratar la infertilidad

Country Status (6)

Country Link
US (1) US7820706B2 (es)
AR (1) AR034037A1 (es)
BR (1) BR0208955A (es)
CA (1) CA2472309C (es)
MX (1) MXPA03009448A (es)
WO (2) WO2002083146A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
WO2007056851A1 (en) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions and methods for enhancing ovulation inducing agents
US20100087407A1 (en) * 2006-08-04 2010-04-08 James Symons use of aromatase inhibitors
WO2011143752A1 (en) * 2010-05-20 2011-11-24 University Of Saskatchewan Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal
WO2014169395A1 (en) 2013-04-19 2014-10-23 University Of Saskatchewan Aromatase inhibitor-releasing intravaginal device
RU2527166C1 (ru) * 2013-07-26 2014-08-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО РостГМУ Минздрава России) Способ моделирования синдрома хронической ановуляции
EP3582799A1 (en) * 2017-02-17 2019-12-25 Celmatix Inc. Methods for assessing the probability of achieving ongoing pregnancy and informing treatment therefrom

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845227A (en) * 1984-06-18 1989-07-04 Eli Lilly And Company Aromatase inhibitors from azoles
DE4330237C2 (de) * 1993-09-02 1995-11-30 Schering Ag 1-Methylsubstituierte Androsta-1,4-dien-3,17-dione, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE4330023C2 (de) 1993-09-06 2001-11-29 Koenig & Bauer Ag Vorrichtung zum Klemmen und Spannen einer biegsamen Druckplatte
DE19622457A1 (de) * 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation

Also Published As

Publication number Publication date
US20040235804A1 (en) 2004-11-25
CA2472309A1 (en) 2002-10-24
WO2002083146A1 (en) 2002-10-24
US7820706B2 (en) 2010-10-26
WO2002083239A1 (en) 2002-10-24
CA2472309C (en) 2010-12-07
BR0208955A (pt) 2004-10-19
MXPA03009448A (es) 2004-05-24

Similar Documents

Publication Publication Date Title
CR6458A (es) Composiciones de valdecoxib
BR9306042A (pt) Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
BR0115392A (pt) Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
UY27186A1 (es) Formulación farmacéutica
DK1011653T3 (da) Anvendelse af xanthophyller i medikamenter til forbedring af varigheden af muskelfunktion eller behandling af muskelforstyrrelser eller -lidelser
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
ES2181770T3 (es) Formulacion combinada farmaceutical para la contracepcion hormonal.
Casu et al. Atypical afta major healing after photodynamic therapy
AR034037A1 (es) Inhibidor de aromatasa en dosis multiples para tratar la infertilidad
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
CY1108648T1 (el) Αναστολεας της αρωματασης σε μια δοση για την θεραπευτικη αντιμετωπιση της υπογόνιμοτήτας
Panchal et al. A comprehensive review of alternative therapeutic approaches for nausea and vomiting relief in pregnancy
CO5090882A1 (es) Nueva vacuna y procedimiento de uso des transmitidas sexualmente
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
AR010623A1 (es) Paquete de asistencia al paciente y metodo para el cumplimiento de tratamientos complejos de medicinas
AR012751A1 (es) Sales de hidrogeno tartrato de (r) -3-n,n-diciclobutilamino-8-fluoro-3,4 -dihidro-2h-1-benzopiran-5-carboxamida, su uso para la fabricacion de medicamentos para tratar trastornos de snc y trastornos medicos relacionados y procedimiento para la fabricacion de dichas sales
BR112022026086A2 (pt) Métodos para tratar câncer ou doença de von-hippel lindau e para tratar carcinoma de célula renal, kit, e, uso de uma combinação terapêutica
AR034310A1 (es) Inhibicion de aromatasa para mejorar la reproduccion asistida
ES2211996T3 (es) Agentes de union a receptores de acido hialuronico y su uso para el tratamiento de tumores o de reestenosis.
ATE283059T1 (de) Verwendung einer pollenextrakt-hältigen verbindung zur behandlung von reizbarkeit
WO2002074315A8 (de) Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
AR023464A1 (es) Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados
AR012702A1 (es) Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente

Legal Events

Date Code Title Description
FB Suspension of granting procedure